AEGiS-PRn: Japanese Patent Office Issues Patent To CEL-SCI Corporation On AIDS Diagnostic Kit

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Japanese Patent Office Issues Patent To CEL-SCI Corporation On AIDS Diagnostic Kit

PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 13 November 1996

ALEXANDRIA, Va., Nov. 13 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI) announces today that the Japanese Patent Office has issued a patent on the diagnostic use of CEL-SCI's HGP-30 technology in AIDS. Japan constitutes one of the largest pharmaceutical markets in the world and is a major gateway into Asia, an area with rapid HIV growth.

The HGP-30 diagnostic test for AIDS is currently being developed at the University of Maryland with a grant from the State of Maryland. The overall purpose of this project is to develop an ELISA based diagnostic kit which measures levels of antibodies binding to HIV-1 p17 peptides in serum.

CEL-SCI hopes to ultimately use the test as a routine monitoring test for disease progression in HIV infected adults and children. CEL-SCI believes that an ELISA based test would be easier and cheaper to use than the current PCR test.

CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. The Company is developing immune based treatments for cancer, AIDS and tuberculosis.

Recently, CEL-SCI Corporation signed a collaborative agreement with the U.S. Navy to jointly develop a malaria vaccine as well as a collaboration agreement with Northeastern Ohio University College of Medicine to jointly develop a herpes vaccine.

"CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at http://www.prnewswire.com on the Internet."

CONTACT: Geert Kersten, Chief Executive Officer, of CEL-SCI, 703-549-5293

Keywords: HIV; IMMUNOTHERAPY; IMMUNE BASED; HERPES

Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
961113
PR961114

Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .